Wu K, Eng E, Knox R, Chen S
Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
Arch Biochem Biophys. 2001 Jan 1;385(1):203-8. doi: 10.1006/abbi.2000.2144.
The rat form of DT-diaphorase (NAD(P)H: quinone acceptor oxidoreductase; EC 1.6.99.2) is more effective than the human form in activating prodrugs such as CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Our site-directed mutagenesis study has revealed that residue 104 (Tyr in the rat enzyme and Gln in the human enzyme) is an important residue responsible for the catalytic differences between the rat and the human enzymes in the activation of CB 1954 (S. Chen et al., 1997, J. Biol. Chem. 272, 1437-1439). The human mutant Q104Y is capable of reducing CB 1954 at a rate identical to that of the wild-type rat DT-diaphorase. In the present study, we prepared both the wild-type human DT-diaphorase- and the mutant Q104Y-expressing MDA-MB-231 breast cancer cell lines using the cDNA transfection method. The MDA-MB-231 cell line is homozygous for a P187S mutation in the DT-diaphorase gene and has no detectable DT-diaphorase activity. Stable clones for the wild-type transfected cells had the DT-diaphorase activity ranged from 0.1 to 3.8 micromol of DCIP reduced/min/mg of protein and the clones for Q104Y transfected cells had the activity ranged from 0.06 to 1.58 micromol of DCIP reduced/min/mg of protein. Furthermore, in contrast to the cells transfected with only expression vector that were not sensitive to CB 1954 treatment, the wild-type and Q104Y-expressing cells were capable of the reductive activation of CB 1954, resulting in cell eradication. Our data showed that cell killing by CB 1954 followed a dose and incubation-time dependent manner. It was also found that the cell survival upon the treatment of CB 1954 was related to the expressed DT-diaphorase activity in these cells. In the presence of 75 microM CB 1954, a 50% cell killing was achieved in cells containing Q104Y and the wild-type DT-diaphorase with the activity at approximately 0.67 and 3.8 micromol of DCIP reduced/min/mg of protein, respectively. These results agree well with those of the in vitro enzyme assays that show that Q104Y is significantly more active than the wild-type DT-diaphorase in the activation of CB 1954. Finally, the in vivo activation of CB 1954 was demonstrated with a nude mouse model using Q104Y-transfected MDA-MB-231 cells. These studies reveal that DT-diaphorase can activate CB 1954, and human Q104Y mutant enzyme is more active than the wild-type enzyme in the intracellular reductive activation of CB 1954.
大鼠形式的DT-黄递酶(NAD(P)H:醌受体氧化还原酶;EC 1.6.99.2)在激活诸如CB 1954(5-(氮丙啶-1-基)-2,4-二硝基苯甲酰胺)等前药方面比人类形式更有效。我们的定点诱变研究表明,第104位残基(大鼠酶中为Tyr,人类酶中为Gln)是导致大鼠和人类酶在激活CB 1954时催化差异的重要残基(S. Chen等人,1997年,《生物化学杂志》272卷,1437 - 1439页)。人类突变体Q104Y能够以与野生型大鼠DT-黄递酶相同的速率还原CB 1954。在本研究中,我们使用cDNA转染方法制备了表达野生型人类DT-黄递酶和突变体Q104Y的MDA-MB-231乳腺癌细胞系。MDA-MB-231细胞系在DT-黄递酶基因中存在P187S突变的纯合子,且没有可检测到的DT-黄递酶活性。野生型转染细胞的稳定克隆的DT-黄递酶活性范围为每分钟每毫克蛋白质还原0.1至3.8微摩尔的DCIP,Q104Y转染细胞的克隆的活性范围为每分钟每毫克蛋白质还原0.06至1.58微摩尔的DCIP。此外,与仅转染表达载体且对CB 1954处理不敏感的细胞不同,表达野生型和Q104Y的细胞能够对CB 1954进行还原激活,从而导致细胞根除。我们的数据表明,CB 1954导致的细胞杀伤呈剂量和孵育时间依赖性。还发现,用CB 1954处理后的细胞存活与这些细胞中表达的DT-黄递酶活性有关。在存在75微摩尔CB 1954的情况下,在含有Q104Y和野生型DT-黄递酶且活性分别约为每分钟每毫克蛋白质还原0.67和3.8微摩尔DCIP的细胞中实现了50%的细胞杀伤。这些结果与体外酶分析结果非常吻合,体外酶分析表明Q104Y在激活CB 1954方面比野生型DT-黄递酶活性显著更高。最后,使用Q104Y转染的MDA-MB-231细胞的裸鼠模型证明了CB 1954在体内的激活。这些研究表明,DT-黄递酶可以激活CB 1954,并且人类Q104Y突变酶在CB 1954的细胞内还原激活方面比野生型酶更具活性。